You are here: Home » Current Affairs » Coronavirus » News
Business Standard

US ban on export of critical raw materials to limit vaccine supply: Serum

SII, the world's biggest vaccine maker, has licensed the AstraZeneca/Oxford University product and will soon start bulk-manufacturing the Novavax shot

Topics
Coronavirus | Coronavirus Vaccine | Serum Institute of India

Reuters  |  New Delhi 

Adar Poonawalla, CEO, Serum Institute
Adar Poonawalla, CEO, Serum Institute

A temporary US ban on exports of critical raw materials could limit the production of vaccines by companies such as the (SII), its chief executive said in a World Bank panel discussion on Thursday.

SII, the world's biggest vaccine maker, has licensed the AstraZeneca/Oxford University product and will soon start bulk-manufacturing the Novavax shot.

"There are a lot of bags, filters and critical items that manufacturers need," Adar Poonawalla said. "The Novavax vaccine, which we are a major manufacturer of, needs these items from the U.S."

He said the recent invocation of the U.S. Defence Production Act to preserve vaccine raw materials for its own companies went against the global goal of sharing vaccines equitably.

The White House said this week it had used the act to help drugmaker Merck & Co produce Johnson & Johnson's COVID-19 vaccine.

"This really needs to be looked at because if they are talking about building capacity all over the world, the sharing of these critical raw materials, which just can't be replaced in a matter of six months or a year, is going to become a critical limiting factor," Poonawalla said.

India's Biological E has tied up with J&J to potentially contract manufacture up to 600 million doses of its vaccine per year. They have signed an initial deal but production volumes have not been agreed upon.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, March 05 2021. 18:54 IST
RECOMMENDED FOR YOU